Treace's 5-Year Lapiplasty Data Shows 0.8% Recurrence, Boosting Clinical Case
TMCI has more than doubled off its 52-week low of $1.17 on light trading volume (0.3× avg).
Summary
Treace presented three clinical studies at AOFAS 2026, headlined by 5-year ALIGN3D data showing a 0.8% radiographic recurrence rate (HVA>20°) for the Lapiplasty procedure. The MTA3D 2-year interim results and SPRINT SpeedPlate study (96.6% union rate) add further validation. This is the first long-term, prospective evidence for the company's flagship bunion correction system, directly addressing a key adoption barrier for surgeons. The data arrives amid a 4% revenue decline and recent product launches, potentially strengthening the commercial narrative. Watch for any subsequent publication or FDA-related commentary, though no specific regulatory event is scheduled.
At the time of this announcement, TMCI was trading at $4.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $294.6M. The 52-week trading range was $1.17 to $7.61. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.